Use of Commercial Genomic Testing for Prostate Cancer ‘Highly Variable’ in the United States
Investigators evaluated a large sample of commercially insured patients with prostate cancer to assess use of tissue-based gene expression testing.
All articles by Katie Wilkerson
A Single Chromosomal Gain in Cancer Can Either Inhibit or Drive Disease
Although some tumors lack aneuploidy or have few extra chromosomal copies, others have a slew of mutations.
Researchers Find a Cancer-Associated Mutation in the Genome’s “Dark Matter”
The research findings could lead to the development of new therapeutic targets.
Scoring the Risk for Heart Problems in CLL: An Italian Model
New cancer-specific designs are needed to balance out heart and cancer outcomes in the chronic disease setting of CLL.
FDA Calls for Patient Registries to Track Robotically Treated Cancers
Head-to-head comparisons of these types of surgical interventions are still needed, according to the regulatory body.
Checkpoint Inhibitors Boost Cancer Vaccine Research
Researchers are excited about the prospect to use vaccines in combination with checkpoint inhibitors to improve the body’s cancer-fighting ability.
Tackling EBV-Associated Lymphoma: Early Research Finds Overall Survival Benefit After Donor Transplants
Use of experimental T cells that target Epstein-Barr virus proteins in relapsed or refractory lymphoma may improve overall survival.
Predicting Response to Immunotherapy in Late-Stage Melanoma
A new model has the potential to identify patients with melanoma who could benefit from treatment with checkpoint inhibitors.
Bispecific Antibodies in Cancer
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
New Therapeutic Directions in the Management of Prostate Cancer
According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...